Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature

2014 ◽  
Vol 35 (1) ◽  
pp. 251-258 ◽  
Author(s):  
Sepideh Faez ◽  
Ann-Marie Lobo ◽  
Sebastian H. Unizony ◽  
John H. Stone ◽  
George N. Papaliodis ◽  
...  
2021 ◽  
pp. 112067212110676
Author(s):  
Ahmad Abdel-Aty ◽  
Ninani Kombo

Chronic inflammatory diseases can cause significant psychosocial stress in affected patients. Few studies have examined the psychological effects of ocular inflammatory disease and no studies have examined the psychological effects of scleritis. In this study we evaluate the prevalence of mental health disorders in scleritis patients and we conduct a comprehensive review of the literature on the mental health effects of ocular inflammatory diseases. 162 patients (195 eyes) presenting to a tertiary care center with scleritis were identified. At least one comorbid mental health disorder was diagnosed in 35 patients (21.6%), most commonly major depression in 11.7%, generalized anxiety disorder in 9.3%, and substance use disorder in 6.2%. There were no significant differences in the length of an episode of scleritis or in the probability of symptom resolution between patients with a mental health disorder and other patients. In a review of the literature, 30 manuscripts met the inclusion criteria. The majority of manuscripts (83.3%) were focused on uveitis patients. Eight of these studies were focused on patients with uveitis in the context of systemic disease. The most commonly reported mental health disorders reported were anxiety and depression. An average of 31.3% of patients with ocular inflammatory disease had depression and 35.0% had anxiety. Similar to other chronic illnesses, ocular inflammatory disease may be a significant psychosocial stressor. Future studies will further elucidate the relationship between these diseases and mental health.


2014 ◽  
Vol 35 (4) ◽  
pp. 1111-1115 ◽  
Author(s):  
Maria Chiara Gerardi ◽  
Iolanda Maria Rutigliano ◽  
Rossana Scrivo ◽  
Roberta Priori ◽  
Valeria Riccieri ◽  
...  

RMD Open ◽  
2019 ◽  
Vol 5 (1) ◽  
pp. e000906 ◽  
Author(s):  
Cassandra Calabrese ◽  
Laura C Cappelli ◽  
Marie Kostine ◽  
Elizabeth Kirchner ◽  
Tawnie Braaten ◽  
...  

ObjectiveTo assess whether the polymyalgia rheumatica (PMR)-like syndrome reported as an immune related adverse event (irAE) from checkpoint inhibitor therapy is consistent with the 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) provisional criteria for PMR.MethodsThe cases were derived from two sources. Group 1 represents reported cases from three contributing centres. Group 2 was derived from a systematic review of the literature searching for all cases reported as PMR or PMR-like illness associated with checkpoint inhibitor therapy. Cases were assessed for the quality of reporting and then analysed to determine whether they fulfilled the 2012 EULAR/ACR provisional criteria for PMR.ResultsA total of 49 patients were included for analysis. Among the entire group, 37 (75%) were designated ‘complete’ indicating that they had sufficient data to reliably apply the 2012 EULAR/ACR criteria. 28 (75%) cases fulfilled complete criteria for PMR. A number of cases also demonstrated some clinical features unusual for idiopathic PMR.ConclusionThis study suggests a high proportion of reported cases of checkpoint inhibitor-related PMR fulfil preliminary criteria for PMR, yet in one quarter clinical details were incomplete making verification problematic. Furthermore, in the absence of a gold standard for the diagnosis of PMR, the relationship of checkpoint inhibitor-related PMR to the idiopathic form remains unclear.


Author(s):  
K. Matthew McKay ◽  
Nicholas Apostolopoulos ◽  
Brian Chou ◽  
Thellea K. Leveque ◽  
Russell N. Van Gelder

2018 ◽  
Vol 56 (01) ◽  
pp. E2-E89
Author(s):  
D Reher ◽  
C Schramm ◽  
F Brinkert ◽  
A Lohse ◽  
C Weiler-Normann

2019 ◽  
Vol 81 (1) ◽  
pp. 14-17
Author(s):  
Yuka KUNIMI ◽  
Yasunori OHGA ◽  
Kotaro ITO ◽  
Shinichi HIROSE ◽  
Shinichi IMAFUKU

Sign in / Sign up

Export Citation Format

Share Document